TY  - JOUR
AU  - Blancas, Isabel
AU  - Martin-Perez, Francisco J
AU  - Garrido, Jose M
AU  - Rodriguez-Serrano, Fernando
PY  - 2020
DO  - 10.1016/j.breast.2020.09.001
UR  - http://hdl.handle.net/10668/16317
T2  - Breast (Edinburgh, Scotland)
AB  - Trastuzumab is a drug used in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring should be a priority. The purpose of this study is to...
LA  - en
PB  - Churchill Livingstone
KW  - Breast cancer
KW  - Cardiotoxicity
KW  - Early diagnosis
KW  - HER2
KW  - NT-proBNP
KW  - Trastuzumab
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - Biomarkers, Pharmacological
KW  - Breast Neoplasms
KW  - Cardiotoxicity
KW  - Diabetes Mellitus
KW  - Drug Monitoring
KW  - Female
KW  - Heart Disease Risk Factors
KW  - Heart Failure
KW  - Humans
KW  - Logistic Models
KW  - Middle Aged
KW  - Natriuretic Peptide, Brain
KW  - Peptide Fragments
KW  - Predictive Value of Tests
KW  - Receptor, ErbB-2
KW  - Retrospective Studies
KW  - Stroke Volume
KW  - Trastuzumab
KW  - Ventricular Function, Left
TI  - NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
TY  - research article
VL  - 54
ER  -